NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TOVX

Theriva Biologics Inc

Jul 01 • 04:00PM ET

0.4380

Dollar change +0.0042
Percentage change 0.97	%

Healthcare • Biotechnology • USA • AMEX

Peers: BPMC AXSM ARCT FATE AVDL ACET ADAP XOMA AVIR CRBP

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-20.68	Insider Own	1.04%	Shs Outstand	9.06M	Perf Week	0.00%
Market Cap	3.97M	Forward P/E	-	EPS next Y	-5.78	Insider Trans	0.00%	Shs Float	8.96M	Perf Month	-6.19%
Enterprise Value	-3.19M	PEG	-	EPS next Q	-0.78	Inst Own	2.11%	Short Float	2.78%	Perf Quarter	-60.18%
Income	-24.81M	P/S	-	EPS this Y	79.72%	Inst Trans	27.17%	Short Ratio	0.18	Perf Half Y	-72.28%
Sales	0.00M	P/B	0.08	EPS next Y	-49.74%	ROA	-61.35%	Short Interest	0.25M	Perf YTD	-74.97%
Book/sh	5.57	P/C	0.40	EPS next 5Y	36.86%	ROE	-100.01%	52W High	7.37 -94.06%	Perf Year	-92.79%
Cash/sh	1.10	P/FCF	-	EPS past 3/5Y	26.32% 39.99%	ROIC	-139.93%	52W Low	0.40 8.96%	Perf 3Y	-99.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.18% 8.80%	Perf 5Y	-99.67%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	28.06%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-100.00%
Dividend Ex-Date	Dec 27, 2007	Quick Ratio	1.53	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.68	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.53	EPS Q/Q	79.36%	SMA20	-4.82%	Beta	0.82	Target Price	7.00
Payout	-	Debt/Eq	0.18	Sales Q/Q	-	SMA50	-37.82%	Rel Volume	0.07	Prev Close	0.43
Employees	22	LT Debt/Eq	0.14	Earnings	May 14 BMO	SMA200	-67.47%	Avg Volume	1.40M	Price	0.44
IPO	Apr 05, 1993	Option/Short	No / Yes	EPS/Sales Surpr.	63.01% -	Trades		Volume	97,934	Change	0.97%

May-27-25 08:00AM	Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer (GlobeNewswire) -5.49%
May-14-25 08:40AM	Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial Results (GlobeNewswire)
08:22AM	Theriva Biologics: Q1 Earnings Snapshot (Associated Press Finance)
May-08-25 04:30PM	Theriva Biologics Announces Closing of $7.5 Million Public Offering (GlobeNewswire) -20.59% -17.62%
May-07-25 09:30AM	Theriva Biologics announces pricing of $7.5M public offering (Seeking Alpha) -40.44%
09:17AM	Loading…
09:17AM	Theriva Biologics Announces Pricing of $7.5 Million Public Offering (GlobeNewswire)
07:00AM	Theriva Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients (GlobeNewswire)
Apr-10-25 08:00AM	Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire) +11.43%
Mar-31-25 08:00AM	Theriva Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (GlobeNewswire)
Mar-19-25 08:10AM	Theriva Biologics to Present at the 2025 NeauxCancer Conference (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-06-25 04:10PM	Theriva Biologics Reports Full-Year 2024 Operational Highlights and Financial Results (GlobeNewswire)
Mar-05-25 04:05PM	Theriva Biologics to Participate in the Q1 Investor Summit Virtual (GlobeNewswire)
Dec-05-24 08:00AM	Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire)
Nov-12-24 08:23AM	Theriva Biologics: Q3 Earnings Snapshot (Associated Press Finance) -23.12%
08:00AM	Loading…
08:00AM	Theriva Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results (GlobeNewswire)
Oct-31-24 04:05PM	Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant (GlobeNewswire) +36.30%
Oct-16-24 08:00AM	Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma (GlobeNewswire) +5.04%
Oct-03-24 10:45AM	Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients (Benzinga) +44.35%
08:00AM	Theriva Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire)
Sep-26-24 09:06PM	Theriva Biologics Announces Pricing of $2.5 Million Public Offering (GlobeNewswire) -13.92% -26.96%
Sep-23-24 08:00AM	Theriva Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -10.00%
Sep-16-24 08:00AM	Theriva Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program (GlobeNewswire) -5.17%
Aug-26-24 11:51AM	Upcoming Stock Splits This Week (August 26 to August 30) Stay Invested (TipRanks) -8.47%
Aug-16-24 04:05PM	Theriva Biologics Announces Reverse Stock Split (GlobeNewswire) -30.21%
Aug-13-24 08:09AM	Theriva Biologics: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Theriva Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results (GlobeNewswire)
Jul-31-24 08:15AM	Theriva Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma (GlobeNewswire) -16.01%
May-23-24 08:15AM	Theriva Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -8.56%
May-14-24 08:00AM	Theriva Biologics to Participate in the A.G.P. Virtual Healthcare Conference (GlobeNewswire)
07:19AM	Loading…
May-07-24 07:19AM	Theriva Biologics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Theriva Biologics Reports First Quarter 2024 Operational Highlights and Financial Results (GlobeNewswire)
Apr-25-24 08:15AM	Theriva Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +11.22%
Apr-23-24 07:00AM	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma (GlobeNewswire) -8.30%
Apr-22-24 04:35PM	Theriva Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting (GlobeNewswire)
Apr-08-24 08:00AM	Theriva Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting (GlobeNewswire)
Mar-26-24 08:42AM	Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript (Insider Monkey) -7.18%
Mar-25-24 10:38PM	Q4 2023 Theriva Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -5.05%
07:30AM	Theriva Biologics Reports Full-Year 2023 Operational Highlights and Financial Results (GlobeNewswire)
Mar-19-24 08:00AM	Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results (GlobeNewswire)
Mar-11-24 08:00AM	Theriva Biologics to Participate in the BIO-Europe Spring Conference (GlobeNewswire)
Feb-07-24 08:00AM	Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +14.58%
Jan-16-24 08:00AM	Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference (GlobeNewswire)
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-20-23 05:56PM	Theriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call Transcript (Insider Monkey) +9.73%
Nov-14-23 03:14AM	Q3 2023 Theriva Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -10.86%
Nov-13-23 08:15AM	Theriva Biologics: Q3 Earnings Snapshot (Associated Press Finance) -6.34%
08:00AM	Theriva Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Nov-06-23 04:05PM	Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire) +7.23% -11.28%
Nov-02-23 04:15PM	Theriva Biologics to Participate in the BIO-Europe Conference (GlobeNewswire)
08:00AM	Theriva Biologics and Sant Joan de Déu-Barcelona Childrens Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer (GlobeNewswire)
Nov-01-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now (GlobeNewswire)
Oct-23-23 07:00AM	Theriva Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023 (GlobeNewswire)
Oct-16-23 08:00AM	Theriva Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) +5.90%
Sep-28-23 08:00AM	Theriva Biologics to Participate in the Emerging Growth Conference (GlobeNewswire)
Aug-08-23 10:43PM	Q2 2023 Theriva Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
08:37AM	Theriva Biologics: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Theriva Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Aug-02-23 07:00AM	Theriva Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +5.68%
Aug-01-23 04:05PM	Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Jun-27-23 04:10PM	Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer (GlobeNewswire) +16.56% +14.79%
May-23-23 08:00AM	Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery (GlobeNewswire)
May-11-23 10:22PM	Q1 2023 Theriva Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Theriva Biologics: Q1 Earnings Snapshot (AP Finance)
08:00AM	Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
May-04-23 08:00AM	Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire) +14.01%
Apr-13-23 08:00AM	Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire) +7.58%
Mar-30-23 08:00AM	Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
Mar-24-23 04:05PM	Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
Mar-20-23 08:00AM	Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
Feb-16-23 12:05PM	Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire)
Jan-17-23 04:05PM	Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) +7.93%
08:00AM	Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Jan-09-23 08:00AM	Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors (GlobeNewswire) +12.41%
Dec-06-22 07:00AM	Sidoti's December Small-Cap Virtual Conference (ACCESSWIRE)
Dec-01-22 08:00AM	Theriva Biologics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-22 04:45PM	Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results (GlobeNewswire)
07:00AM	Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results (GlobeNewswire)
Nov-03-22 04:05PM	Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results (GlobeNewswire)
08:00AM	Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients (GlobeNewswire)
Oct-31-22 08:00AM	Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics (GlobeNewswire)
Oct-24-22 08:00AM	Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck (GlobeNewswire) -19.57%

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TOVX

Theriva Biologics Inc

Upgrade your FINVIZ experience